Investigational New Drugs

, Volume 30, Issue 4, pp 1646–1651

SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma

  • Anthony B. El-Khoueiry
  • Cathryn J. Rankin
  • Edgar Ben-Josef
  • Heinz-Josef Lenz
  • Philip J. Gold
  • R. Darryl Hamilton
  • Rangaswamy Govindarajan
  • Cathy Eng
  • Charles D. Blanke
PHASE II STUDIES

DOI: 10.1007/s10637-011-9719-0

Cite this article as:
El-Khoueiry, A.B., Rankin, C.J., Ben-Josef, E. et al. Invest New Drugs (2012) 30: 1646. doi:10.1007/s10637-011-9719-0

Summary

Objectives Gallbladder and cholangiocarcinomas represent a heterogeneous group of malignant diseases that commonly present at an advanced stage and have limited therapeutic options. Based on the role of the Ras-Raf-Mek-Erk pathway and the VEGF axis in biliary carcinomas, we conducted a phase II study of sorafenib in patients with advanced biliary cancers. Methods Eligible patients had no prior therapy for metastatic or unresectable disease. Sorafenib was administered at 400 mg po twice daily continuously. Results The study was terminated after the first stage of accrual due to failure to meet the primary objective. A confirmed response rate of 0% (0%–11%) was observed. Thirty-nine percent of patients demonstrated stable disease (including 2 with unconfirmed PR). PFS was 3 months (95% CI: 2–4 months) and OS 9 months (95% CI: 4–12 months). The most common grade 3 and 4 toxicities included hand-foot skin reaction (13%), bilirubin elevation (13%), venous thromboembolism (10%), AST/ALT elevation (10%) and elevated alkaline phosphatase (10%). Conclusion While treatment with sorafenib did not result in objective responses, patients with biliary cancers receiving this drug had some therapeutic benefit. Additional studies with sorafenib in combination with chemotherapy or other targeted agents may be warranted.

Keywords

SorafenibGallbladder cancerCholangiocarcinomaBiliary cancer

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Anthony B. El-Khoueiry
    • 1
  • Cathryn J. Rankin
    • 2
  • Edgar Ben-Josef
    • 3
  • Heinz-Josef Lenz
    • 1
  • Philip J. Gold
    • 4
  • R. Darryl Hamilton
    • 5
  • Rangaswamy Govindarajan
    • 6
  • Cathy Eng
    • 7
  • Charles D. Blanke
    • 8
  1. 1.University of Southern California/Norris Comprehensive Cancer CenterLos AngelesUSA
  2. 2.SWOG Statistical CenterSeattleUSA
  3. 3.University of MichiganAnn ArborUSA
  4. 4.Puget Sound Oncology Consortium/Swedish Cancer InstituteSeattleUSA
  5. 5.University of Mississippi Medical CenterJacksonUSA
  6. 6.University of Arkansas/Winthrop Rockefeller Cancer InstituteLittle RockUSA
  7. 7.University of Texas/MD Anderson Cancer CenterHoustonUSA
  8. 8.University of British Columbia, and BC Cancer AgencyVancouverCanada